Omacetaxine mepesuccinate: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

22 January 2024

  • curprev 23:3223:32, 22 January 2024‎ Edzelco talk contribs‎ 17,319 bytes +17,319‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Omacetaxine mepesuccinate (SYNRIBO) |aOrAn=an |drugClass=injection |indicationType=treatment |indication=adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI) |fdaLIADAdult=*Induction Dose: 1.25 mg/m2 administered by subcutaneous injection twice daily for 14 consecutive days of a 28-day cycle. *Maint..."
Retrieved from "https://www.wikidoc.org/index.php/Omacetaxine_mepesuccinate"